
News|Articles|November 1, 2006
Pipeline Preview (November 2006)
Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Fenebrutinib trials show success in treating both relapsing and progressive multiple sclerosis
2
Study explores growth hormone signaling in bladder cancer
3
Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.
4
Fecal Transplants with Immunotherapy Extend Survival in Advanced Melanoma Patients
5


















































